|
Characteristic
|
No. of patients (%)
|
Univariate analysisaP value
|
|---|
|
Age (years)
|
|
Median (Range)
|
56.5 (34–81)
| |
|
≤ 56: > 56
|
63 (50): 63 (50)
|
.293
|
|
Gender
|
|
Male: Female
|
121 (96.0): 5 (4.0)
|
.077
|
|
Body mass index
|
|
Median (Range)
|
21.4 (15.5–30.0)
| |
|
≤ 21.4: > 21.4
|
64 (50.8): 62 (49.2)
|
.721
|
|
Body surface area
|
|
Median (Range)
|
1.65 (1.3–2.1)
| |
|
≤ 1.65: > 1.65
|
66 (52.4): 60 (47.6)
|
.784
|
|
Eastern Cooperative Oncology Group performance status
|
|
0: 1: 2: 3
|
12 (9.5): 98 (77.8): 15 (11.9): 1 (0.8)
|
.539
|
|
Stage
|
|
I: II: III
|
2 (1.6): 10 (7.9): 114 (90.5)
|
.600
|
|
Tumor location
|
|
U: M: L
|
51 (40.5): 30 (23.8): 20 (15.9)
|
.001
|
|
U + M
|
9 (7.1)
| |
|
U + M + L
|
1 (0.8)
| |
|
M + L
|
15 (11.9)
| |
|
Histology
|
|
Squamous cell carcinoma
|
121 (96.0)
|
.508
|
|
Adenocarcinoma
|
3 (2.4)
| |
|
Poorly differentiated carcinoma
|
2 (1.6)
| |
|
Smoking
|
|
Yes: No
|
114 (90.5): 12 (9.5)
|
.350
|
|
Alcohol
|
|
Yes: No
|
115 (91.3): 11 (8.7)
|
.094
|
|
Hypertension
|
|
Yes: No
|
25 (19.8): 101 (80.2)
|
.418
|
|
Diabetes
|
|
Yes: No
|
15 (11.9): 111 (88.1)
|
.582
|
|
Cardiovascular disease
|
|
Yes: No
|
7 (5.6): 119 (94.4)
|
.097
|
|
Radiation dose (Gray)
|
|
Median (range)
|
61.2 (50–66.6)
| |
|
≤ 60: > 60
|
52 (41.3): 74 (58.7)
|
.238
|
|
Chemotherapy regimen
|
|
Fluoropyrimidine-based
|
118 (93.7)
|
.900
|
|
Taxane-based
|
4 (3.2)
| |
|
Others
|
4 (3.2)
| |
- Abbreviations: L lower thoracic esophagus, M middle thoracic esophagus, U upper thoracic esophagus
- aUnivariate analysis of patients’ characteristics associated with pericardial effusion
